American Century Companies Inc. Acquires 247,505 Shares of Astera Labs, Inc. $ALAB

American Century Companies Inc. boosted its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 754.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 280,296 shares of the company’s stock after buying an additional 247,505 shares during the quarter. American Century Companies Inc. owned approximately 0.17% of Astera Labs worth $54,882,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Assetmark Inc. boosted its stake in Astera Labs by 374.1% in the third quarter. Assetmark Inc. now owns 128 shares of the company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. Clearstead Trust LLC increased its stake in shares of Astera Labs by 46,100.0% during the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in shares of Astera Labs by 68.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after purchasing an additional 194 shares during the period. Manchester Capital Management LLC lifted its stake in Astera Labs by 141.5% in the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after purchasing an additional 283 shares during the last quarter. Finally, Whittier Trust Co. purchased a new position in Astera Labs in the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Jitendra Mohan sold 94,971 shares of Astera Labs stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total transaction of $11,758,359.51. Following the completion of the sale, the chief executive officer owned 1,452,739 shares of the company’s stock, valued at approximately $179,863,615.59. This trade represents a 6.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Philip Mazzara sold 10,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $117.47, for a total value of $1,174,700.00. Following the completion of the transaction, the general counsel owned 128,084 shares in the company, valued at $15,046,027.48. This represents a 7.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 216,792 shares of company stock worth $26,777,569 over the last three months. Corporate insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Loop Capital initiated coverage on Astera Labs in a research report on Thursday. They issued a “buy” rating and a $250.00 target price for the company. Royal Bank Of Canada started coverage on Astera Labs in a research note on Wednesday, January 14th. They set an “outperform” rating and a $225.00 price target for the company. Wall Street Zen cut Astera Labs from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Northland Securities increased their target price on shares of Astera Labs from $175.00 to $195.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings downgraded shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 23rd. Fifteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and an average price target of $195.89.

Astera Labs Trading Up 5.5%

Shares of NASDAQ:ALAB opened at $120.00 on Friday. The company has a 50 day moving average of $153.84 and a 200 day moving average of $170.53. The stock has a market cap of $20.43 billion, a P/E ratio of 98.36, a P/E/G ratio of 2.24 and a beta of 1.74. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.07. The business had revenue of $270.58 million for the quarter, compared to analysts’ expectations of $249.46 million. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The business’s revenue for the quarter was up 91.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.37 EPS. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, equities analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Key Headlines Impacting Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Loop Capital initiated coverage with a “Buy” and a $250 price target (roughly +100% upside vs. current levels), which can attract new buy-side interest and help lift sentiment. Benzinga
• Positive Sentiment: Recent quarterly results showed an EPS and revenue beat plus strong year-over-year revenue growth and positive guidance (Q1 EPS guide provided), supporting a fundamental growth story for the company and giving investors confidence in near-term execution. MarketBeat ALAB
• Positive Sentiment: Multiple sell-side firms have raised targets or maintain Buy/Outperform ratings (JPMorgan, Stifel, Northland, BNP Paribas Exane), and the consensus price target remains well above current trading levels—fuel for momentum traders and longer-term buyers. MarketBeat ALAB
• Neutral Sentiment: Media pieces are debating valuation and whether the stock is “too late” after strong 1‑year gains; these articles can drive retail interest but are mixed in directional impact. Yahoo Finance InsiderMonkey
• Neutral Sentiment: Reported short-interest figures in the feeds show contradictory/erroneous data (zeros and NaN values), so current short-interest signals are unreliable; treat these entries cautiously until corrected data is posted.
• Negative Sentiment: Insider selling: General Counsel Philip Mazzara sold 10,000 shares at about $117.47 (disclosed via SEC Form 4), reducing his ownership. Insider sales can be perceived negatively by some investors even if routine or for diversification/liquidity reasons. SEC Form 4

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.